Tiziana Life Sciences LtdNASDAQ:TLSA
- LAST PRICE0.9450
- TODAY'S CHANGE (%)-0.0149 (-1.5522%)
- Bid / Lots0.9450/ 1
- Ask / Lots0.9451/ 6
- Open / Previous Close0.9700 / 0.9599
- Day Range
- 52 Week Range
- Volume52,395
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 1284 | 0.97 |
| 09:33 ET | 200 | 0.9599 |
| 09:39 ET | 13001 | 0.97 |
| 09:46 ET | 700 | 0.97 |
| 09:48 ET | 200 | 0.97 |
| 09:53 ET | 100 | 0.956 |
| 10:11 ET | 1000 | 0.959 |
| 10:15 ET | 250 | 0.9598 |
| 10:20 ET | 200 | 0.95 |
| 10:29 ET | 7000 | 0.958121 |
| 10:33 ET | 500 | 0.9561 |
| 11:16 ET | 400 | 0.9598 |
| 11:32 ET | 200 | 0.9571 |
| 11:38 ET | 270 | 0.957 |
| 11:43 ET | 900 | 0.95 |
| 12:14 ET | 100 | 0.9598 |
| 12:24 ET | 1430 | 0.95832 |
| 01:06 ET | 150 | 0.9524 |
| 01:08 ET | 1000 | 0.9599 |
| 01:20 ET | 1305 | 0.952451 |
| 01:44 ET | 200 | 0.9531 |
| 01:56 ET | 500 | 0.9599 |
| 02:18 ET | 600 | 0.9501 |
| 02:52 ET | 100 | 0.96 |
| 03:12 ET | 300 | 0.959898 |
| 03:14 ET | 200 | 0.952073 |
| 03:15 ET | 1349 | 0.9575 |
| 03:33 ET | 5082 | 0.9501 |
| 03:35 ET | 1500 | 0.951249 |
| 03:46 ET | 6793 | 0.9513 |
| 03:50 ET | 150 | 0.9513 |
| 04:00 ET | 1232 | 0.945 |
Nov 19, 2024
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association, from 7:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 1, 2024
Oct 30, 2024
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million, from 10:29PM ET on Wednesday Oct 30, 2024 by Dow Jones
10:29PM ET on Wednesday Oct 30, 2024 by Dow JonesPress Release: Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million, from 10:29PM ET on Wednesday Oct 30, 2024 by Dow Jones
10:29PM ET on Wednesday Oct 30, 2024 by Dow JonesTiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study, from 8:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
8:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 105.4M | -5.5x | --- |
Monopar Therapeutics Inc | 106.1M | -9.8x | --- |
Context Therapeutics Inc | 104.2M | -1.6x | --- |
CAMP4 Therapeutics Corp | 105.5M | -1.9x | --- |
INmune Bio Inc | 108.0M | -2.2x | --- |
Anixa Biosciences Inc | 103.0M | -8.5x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer
- Ivor Elrifi
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $105.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 110.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.17 |
Book Value | $0.05 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
